Chemotherapy-Induced Peripheral Neuropathy Market: Industry trends, Drugs, Companies and Analysis by DelveInsight| Solasia, WEX Pharmaceuticals, Asahi Kasei Pharma, ChromaDex, DARA BioSciences

April 23 02:38 2021
Chemotherapy-Induced Peripheral Neuropathy Market: Industry trends, Drugs, Companies and Analysis by DelveInsight| Solasia, WEX Pharmaceuticals, Asahi Kasei Pharma, ChromaDex, DARA BioSciences

Chemotherapy-Induced Peripheral Neuropathy Market

Chemotherapy-Induced Peripheral Neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinums, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors.

DelveInsight’s “Chemotherapy-induced peripheral neuropathy Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Chemotherapy-induced peripheral neuropathy, historical and forecasted epidemiology as well as the Chemotherapy-induced peripheral neuropathy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

Some Facts of Chemotherapy-induced peripheral neuropathy Market Report:

  • Market Size of CIPN was found to be USD 1,435.67 million in 2020
  • In 2017, the incident population of CIPN in the US by cancer type was accounted for 82,082 for Breast Cancer, 60,620 for colorectal cancer. CIPN in Lung Cancer patients were estimated to be 48,724
  • In 2017, incident cases of mild, moderate and severe CIPN in Germany were 33,019; 108,963 and 23,113, respectively.
  • As per DelveInsight’s estimates, Japan accounts for approximately 18.11% of the total incident cases in the 7MM. In 2017, the incident population of chemotherapy induced peripheral neuropathy in Japan was found to be 263,842.
  • The United States showed the highest incident population of CIPN. As per DelveInsight estimates, the US accounts for approximately 41.11% of total cases, for CIPN, in the 7MM countries. In 2017, the incident population of CIPN in the US was estimated to be 598,908.

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cipn-market

 

Scope of CIPN Report:

  • The report covers the descriptive overview of Chemotherapy-induced peripheral neuropathy, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Chemotherapy-induced peripheral neuropathy epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Chemotherapy-induced peripheral neuropathy are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Chemotherapy-induced peripheral neuropathy market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chemotherapy-induced peripheral neuropathy market

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cipn-market

 

Some of Chemotherapy-induced peripheral neuropathy Companies are:

  • Solasia
  • WEX Pharmaceuticals
  • Asahi Kasei Pharma
  • ChromaDex
  • DARA BioSciences
  • Laboratorios Dr. Esteve S.A. (ESTEVE)
  • MediciNova
  • Toray Industries
  • PledPharma
  • And Many Others

 

Some of Chemotherapy-induced peripheral neuropathy Therapies included:

  • SP-04
  • Halneuron
  • Niagen
  • E-52862
  • ART-123
  • KRN 5500
  • MN-166 (Ibudilast)
  • E-52862
  • TRK-750
  • And Many Others

 

Request for Free Sample Report: https://www.delveinsight.com/sample-request/cipn-market

 

Table of Contents:

1. Key Insights

2. Executive Summary of Chemotherapy-induced peripheral neuropathy

3. Competitive Intelligence Analysis for Chemotherapy-induced peripheral neuropathy

4. Chemotherapy-induced peripheral neuropathy: Market Overview at a Glance

5. Chemotherapy-induced peripheral neuropathy: Disease Background and Overview

6. Patient Journey

7. Chemotherapy-induced peripheral neuropathy Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Chemotherapy-induced peripheral neuropathy Treatment

11. Marketed Products

List to be continued in report

12. Emerging Therapies

List to be continued in report

13. Chemotherapy-induced peripheral neuropathy: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Chemotherapy-induced peripheral neuropathy

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for Detailed TOC @ https://www.delveinsight.com/sample-request/cipn-market

 

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/cipn-market